Truist Securities Maintains Buy on Tectonic Therapeutic, Lowers Price Target to $60

Benzinga · 3d ago
Truist Securities analyst Danielle Brill maintains Tectonic Therapeutic (NASDAQ:TECX) with a Buy and lowers the price target from $64 to $60.